Corrigendum to "Targeting mammalian target of rapamycin (mTOR) for health and diseases" (DOI:10.1016/j.drudis.2006.12.008);Targeting mammalian target of rapamycin (mTOR) for health and diseases

Drug Discovery Today

Volumn 12, Issue 3-4, 2007, Pages 112-124

  Tsang, Chi Kwan ^a   Qi, Haiyan ^a   Liu, Leroy F ^a   Zheng, X F Steven ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; AP 23573; CHOLESTEROL; CYCLOSPORIN; EVEROLIMUS; FK 506 BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1; INITIATION FACTOR 4E; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE LKB1; PROTEIN P53; RAPAMYCIN; RAPAMYCIN DERIVATIVE; RHEB PROTEIN; S6 KINASE; TACROLIMUS; TEMSIROLIMUS; TRIACYLGLYCEROL; TUBERIN; UNINDEXED DRUG;

AGING; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG TARGETING; GRAFT REJECTION; GROWTH REGULATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; KIDNEY POLYCYSTIC DISEASE; LIFESPAN; LYMPHOMA; MUCOSA INFLAMMATION; NEPHROTOXICITY; NONHUMAN; OBESITY; PROSTATE CANCER; RESTENOSIS; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 33846569938     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.06.003     Document Type: Erratum

References (103)

1. Yu K., et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer 8 (2001) 249-258
2. Neshat M.S., et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 10314-10319
3. Schuurman H., et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 64 (1997) 32-35
4. Vignot S., et al. mTOR-targeted therapy of cancer with rapamycin derivatives 10.1093/annonc/mdi113. Ann. Oncol. 16 (2005) 525-537
5. Mita M.M., et al. Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR Inhibitor, administered IV daily X 5 every other week in patients (pts) with refractory or advanced malignancies. ASCO Meeting Abstracts 22 Suppl. 14 (2004) 3076
6. Clackson, T. et al. (2003) Broad anti-tumor activity of ap23573, an mTOR inhibitor in clinical development, ASCO Annual Meeting Abstract No: 882
7. Raymond E., et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J. Clin. Oncol. 22 (2004) 2336-2347
8. Murgia M., et al. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int. 49 (1996) 209-216
9. Keith C.T., and Schreiber S.L. PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints. Science 270 (1995) 50-51
10. Brown E.J., et al. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 377 (1995) 441-446
11. Zheng X.F., et al. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell 82 (1995) 121-130
12. Chen J., et al. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 4947-4951
13. Choi J., et al. Structure of the FKBP 1 over(2, ̃)rapamycin complex interacting with the binding domain of human FRAP. Science 273 (1996) 239-242
14. Andrade M.A., and Bork P. HEAT repeats in the Huntington's disease protein. Nat. Genet. 11 (1995) 115-116
15. Kim D., et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110 (2002) 163-175
16. Bertram P.G., et al. Tripartite regulation of Gln3p by TOR, Ure2p and phosphatases. J. Biol. Chem. 275 (2000) 35727-35733
17. Abraham R.T. Identification of TOR signaling complexes: more TORC for the cell growth engine. Cell 111 (2002) 9-12
18. Inoki K., et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat. Cell Biol. 4 (2002) 648-657
19. Inoki K., et al. Signaling by target of rapamycin proteins in cell growth control. Microbiol. Mol. Biol. Rev. 69 (2005) 79-100
20. Nave B.T., et al. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem. J. 344 (1999) 427-431
21. Inoki K., et al. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115 (2003) 577-590
22. Dennis P.B., et al. Mammalian TOR: A homeostatic ATP sensor. Science 294 (2001) 1102-1105
23. Brugarolas J., et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 18 (2004) 2893-2904
24. Feng Z., et al. The coordinate regulation of the p53 and mTOR pathways in cells. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 8204-8209
25. Ai W., et al. Regulation of subtelomeric silencing during stress response. Mol. Cell 10 (2002) 1295-1305
26. Gangloff Y.-G., et al. Disruption of the Mouse mTOR Gene Leads to Early Postimplantation Lethality and Prohibits Embryonic Stem Cell Development. Mol. Cell. Biol. 24 (2004) 9508-9516
27. Dufner A., and Thomas G. Ribosomal S6 kinase signaling and the control of translation. Exp. Cell Res. 253 (1999) 100-109
28. Pende M., et al. S6K1-/-/S6K2-/- Mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol. Cell. Biol. 24 (2004) 3112-3124
29. Lawrence J., and Brunn G. Insulin signaling and the control of PHAS-I phosphorylation. Prog. Mol. Subcell. Biol. 26 (2001) 1-31
30. Tsang C.K., and Zheng X.F.S. Control of ribosome biogenesis by target of rapamycin (TOR). Recent Res. Dev. Mol. Cell Biol. 5 (2004) 135-147
31. Shintani T., and Klionsky D.J. Autophagy in health and disease: a double-edged sword. Science 306 (2004) 990-995
32. Schreiber S.L., and Crabtree G.R. Immunophilins, ligands, and the control of signal transduction. Harvey Lect. 91 (1995) 99-114
33. Ho S., et al. The mechanism of action of cyclosporin A and FK506. Clin. Immunol. Immunopathol. 80 (1996) S40-S45
34. Abraham R., and Wiederrecht G. Immunopharmacology of rapamycin. Annu. Rev. Immunol. 14 (1996) 483-510
35. Kahan B. Emerging strategies for the clinical application of rapamycin. Clin. Biochem. 31 (1998) 341-344
36. Morales J., et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am. J. Transplant. 2 (2002) 436-442
37. Stegall M., et al. Kidney transplantation without calcineurin inhibitors using sirolimus. Transplant. Proc. 35 3 Suppl (2003) 125S-127S
38. Teutonico A., et al. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J. Am. Soc. Nephrol. 16 (2005) 3128-3135
39. Burkhardt H., and Kalden J. Xenobiotic immunosuppressive agents: therapeutic effects in animal models of autoimmune diseases. Rheumatol. Int. 17 (1997) 85-90
40. Woltman A.M., et al. Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. Blood 98 (2001) 174-180
41. Hackstein H., et al. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 101 (2003) 4457-4463
42. Richardson C., et al. PI3-kinase and TOR: PIKTORing cell growth. Semin. Cell Dev. Biol. 15 (2004) 147-159
43. Guertin D., and Sabatini D. An expanding role for mTOR in cancer. Trends Mol. Med. 11 (2005) 353-361
44. Wendel H., et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428 (2004) 332-337
45. Huang S., and Houghton P. Targeting mTOR signaling for cancer therapy. Curr. Opin. Pharmacol. 3 (2003) 371-377
46. Guba M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8 (2002) 128-135
47. Treins C., et al. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J. Biol. Chem. 277 (2002) 27975-27981
48. Hudson C.C., et al. Regulation of hypoxia-inducible factor 1{alpha} expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 22 (2002) 7004-7014
49. Sarbassov D.D., et al. Prolonged rapamycin treatment inhibits mTORC2 Assembly and Akt/PKB. Mol. Cell 22 (2006) 159-168
50. Chan T.-F., et al. A chemical genomics approach toward understanding the global functions of the target of rapamycin protein (TOR). Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 13227-13232
51. Saltiel A., and Kahn C. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414 (2001) 799-806
52. Shapiro A.M.J., et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343 (2000) 230-238
53. McDaniel M.L., et al. Metabolic and autocrine regulation of the mammalian target of rapamycin by pancreatic {beta}-cells. Diabetes 51 (2002) 2877-2885
54. Pende M., et al. Hypoinsulinaemia, glucose intolerance and diminished [beta]-cell size in S6K1-deficient mice. Nature 408 (2000) 994-997
55. Rhodes C.J. Type 2 diabetes-a matter of beta-cell life and death?. Science 307 (2005) 380-384
56. Shah O., et al. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14 (2004) 1650-1656
57. Harrington L.S., et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166 (2004) 213-223
58. Briaud I., et al. Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase b-mediated signaling pathway in {beta}-cells. J. Biol. Chem. 280 (2005) 2282-2293
59. Kim J.E., and Chen J. Regulation of peroxisome proliferator-activated receptor-{gamma} activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes 53 (2004) 2748-2756
60. Cho H., et al. Regulation of adipocyte differentiation and insulin action with rapamycin. Biochem. Biophys. Res. Commun. 321 (2004) 942-948
61. Yeh W., et al. Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 11086-11090
62. Huffman T.A., et al. Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 1047-1052
63. Fox H.L., et al. Amino acids stimulate phosphorylation of p70S6k and organization of rat adipocytes into multicellular clusters. Am. J. Physiol. Cell Physiol. 274 (1998) C206-C213
64. Teleman A., et al. Drosophila Melted modulates FOXO and TOR activity. Dev. Cell 9 (2005) 271-281
65. Um S., et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431 (2004) 200-205
66. Tsukiyama-Kohara K., et al. Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1. Nat. Med. 7 (2001) 1128-1132
67. Frey N., et al. Hypertrophy of the heart: a new therapeutic target?. Circulation 109 (2004) 1580-1589
68. McMullen J.R., et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 109 (2004) 3050-3055
69. Gruntzig A., et al. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N. Engl. J. Med. 301 (1979) 61-68
70. Serruys P.W., et al. Coronary-artery stents. N. Engl. J. Med. 354 (2006) 483-495
71. Poon M., et al. Rapamycin inhibits vascular smooth muscle cell migration. J. Clin. Invest. 98 (1996) 2277-2283
72. Ravikumar B., et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 36 (2004) 585-595
73. Li X., et al. Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J. 272 (2005) 4211-4220
74. Berger Z., et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet. 15 (2006) 433-442
75. de Nobel H., et al. Parallel and comparative analysis of the proteome and transcriptome of sorbic acid-stressed Saccharomyces cerevisiae. Yeast 18 (2001) 1413-1428
76. Bonifati V., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset Parkinsonism. Science 299 (2003) 256-259
77. Crino P.B., and Henske E.P. New developments in the neurobiology of the tuberous sclerosis complex. Neurology 53 (1999) 1384-1390
78. Goodman M., et al. Cortical tuber count: A biomarker indicating neurologic severity of tuberous sclerosis complex. J. Child Neurol. 12 (1997) 85-90
79. Asaki C., et al. Localization of translational components at the ultramicroscopic level at postsynaptic sites of the rat brain. Brain Res. 972 (2003) 168-176
80. Tang S.J., et al. A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 467-472
81. Kapahi P., et al. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr. Biol. 14 (2004) 885-890
82. Kaeberlein M., et al. Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Science 310 (2005) 1193-1196
83. Powers III R.W., et al. Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes Dev. 20 (2006) 174-184
84. Holzenberger M., et al. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 421 (2003) 182-187
85. Bonafe M., et al. Polymorphic variants of insulin-like growth factor I (IGF-I) receptor and phosphoinositide 3-kinase genes affect IGF-I plasma levels and human longevity: cues for an evolutionarily conserved mechanism of life span control. J. Clin. Endocrinol. Metab. 88 (2003) 3299-3304
86. Masoro E.J. Subfield History: caloric restriction, slowing aging, and extending life. Sci. Aging Knowledge Environ. 2003 (2003) RE2
87. Gredilla R., and Barja G. Minireview: the role of oxidative stress in relation to caloric restriction and longevity. Endocrinology 146 (2005) 3713-3717
88. Breese C.R., et al. Influence of age and long-term dietary restriction on plasma insulin-like growth factor-1 (IGF-1), IGF-1 gene expression, and IGF-1 binding proteins. J. Gerontol. 46 (1991) B180-B187
89. Melendez A., et al. Autophagy genes are essential for dauer development and life-span extension in C. elegans. Science 301 (2003) 1387-1391
90. Lin K., et al. daf-16: An HNF-3/forkhead family member that can function to double the life-span of Caenorhabditis elegans. Science 278 (1997) 1319-1322
91. Jia K., et al. The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span. Development 131 (2004) 3897-3906
92. Shillingford J.M., et al. From the Cover: The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 5466-5471
93. Ritacco F.V., et al. Production of novel rapamycin analogs by precursor-directed biosynthesis. Appl. Environ. Microbiol. 71 (2005) 1971-1976
94. Lowden P., et al. New rapamycin derivatives by precursor-directed biosynthesis. ChemBioChem 5 (2004) 535-538
95. Gregory M., et al. Isolation and characterization of pre-rapamycin, the first macrocyclic intermediate in the biosynthesis of the immunosuppressant rapamycin by S. hygroscopicus. Angew. Chem. Int. Ed. Engl. 43 (2004) 2551-2553
96. Shuker S.B., et al. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274 (1996) 1531-1534
97. Babine R.E., et al. Design, synthesis and X-ray crystallographic studies of novel FKBP-12 ligands. Bioorg. Med. Chem. Lett. 5 (1995) 1719-1724
98. Gregory D., et al. Atomic structure of the rapamycin human immunophilin FKBP-12 complex. J. Am. Chem. Soc. 113 (1991) 7433-7434
99. Sarbassov D.D., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22 (2006) 159-168
100. Zheng X., et al. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell 82 (1995) 121-130
101. Knight Z.A., et al. A pharmacological map of the PI3-K family defines a role for p110[alpha] in insulin signaling. Cell 125 (2006) 733-747
102. Fan Q.-W., et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9 (2006) 341-349
103. McMahon L.P., et al. Farnesylthiosalicylic acid inhibits mammalian target of rapamycin (mTOR) activity both in cells and in vitro by promoting dissociation of the mTOR-raptor complex. Mol. Endocrinol. 19 (2005) 175-183